Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Psoriasis Health Center

Font Size

New Psoriasis Drug Shows Promise

Plaque Psoriasis Drug, Called Ustekinumab, Has Been Submitted for FDA's Review
WebMD Health News
Reviewed by Louise Chang, MD

May 15, 2008 -- A new biologic drug called ustekinumab may ease plaque psoriasis, two new studies show.

Ustekinumab targets two inflammatory chemicals called interleukins 12 and 23, which are involved in psoriasis.

Centocor, the drug company that makes ustekinumab, has already submitted the drug for the FDA's review. The two new studies, published in The Lancet, are ustekinumab's most recent clinical trials.

Together, the two studies included nearly 2,000 adults in the U.S., Canada, and Europe who have moderate to severe plaque psoriasis. They were randomly assigned to get a shot of ustekinumab or a placebo when the study started and an additional shot a month later.

Three months after the study started, 66% to 75% of patients taking ustekinumab had reduced their psoriasis symptoms by at least 75%. Only about 3% of those taking the placebo met that benchmark.

At that point, all of the patients got an injection of ustekinumab every three months, which eased psoriasis in most patients who had been taking the placebo. Some patients with more modest improvements benefited when they got the study's highest dose given every two months instead of every three months.

The patients had to keep taking ustekinumab to maintain their results. When they stopped, the benefits gradually faded.

Ustekinumab was generally well tolerated, but the researchers note that follow-up studies are needed to check the drug's safety in the long run.

An editorial published with the studies states that while ustekinumab compares favorably with the best available therapies for psoriasis, "many questions remain," including effectiveness in patients with psoriatic arthritis and long-term safety.

Centocor funded both of the studies; several of the researchers are Centocor employees. The editorialists note that they are conducting psoriasis studies funded by other drug companies.

Today on WebMD

Woman sitting in front of UV lights
About 7.5 million people in the U.S. Get the facts.
stress and psoriasis
What might spark your psoriasis today?
woman bathing
Slideshow: Home Remedies For Psoriasis
woman applying lotion
It starts in the immune system. Read on.
Top Psoriasis Treatments To Try At Home
Woman sitting in front of UV lights
Beware Miracle Diets For Psoriasis
Psoriasis Laser Therapy
10 Questions About Psoriasis To Ask Your Doctor
psoriasis on elbow
Psoriasis (Moderate to Severe)
Psoriatic Arthritis Do You Know The Symptoms